Efficacy of Naftopidil in Patients with Overactive Bladder Associated with Benign Prostatic Hyperplasia: Prospective Randomized Controlled Study to Compare Differences in Efficacy Between Morning and Evening Medication
-
- Sakai, Hideki
- The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences
-
- Igawa, Tsukasa
- The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences
-
- Onita, Toru
- The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences
-
- Furukawa, Masataka
- The Department of Urology, Sasebo General Hospital
-
- Hakariya, Tomoaki
- The Department of Urology, Nagasaki Medical Center
-
- Hayashi, Mikio
- The Department of Urology, Nagasaki Medical Center
-
- Matsuya, Fukuzo
- The Department of Urology, Isahaya General Hospital
-
- Shida, Yohei
- The Department of Urology, Isahaya General Hospital
-
- Nishimura, Naoki
- The Department of Urology, Nagasaki Prefecture Shimabara Hospital
-
- Yogi, Yasuo
- The Department of Urology, Nagasaki Prefecture Shimabara Hospital
-
- Tsurusaki, Toshifumi
- The Department of Urology, Nagasaki Municipal Hospital
-
- Takehara, Kousuke
- The Department of Urology, St Francis Hospital
-
- Nomata, Koichiro
- The Department of Urology, Goto Chuoh Hospital
-
- Shiraishi, Kazutaka
- The Department of Urology, Goto Chuoh Hospital
-
- Shono, Takefumi
- The Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences
-
- Aoki, Daiyu
- 五島中央病院泌尿器科
-
- Kanetake, Hiroshi
- 長崎大学大学院医歯薬学総合研究科腎泌尿器病態学
Bibliographic Information
- Other Title
-
- 過活動膀胱症状を有する前立腺肥大症に対するナフトピジルの有効性の検討 : 朝投与と夕投与の前向き無作為化比較試験
- カカツドウ ボウコウ ショウジョウ オ ユウスル ゼンリツセン ヒダイショウ ニ タイスル ナフトピジル ノ ユウコウセイ ノ ケントウ アサ トウヨ ト ユウ トウヨ ノ マエムキ ムサクイカ ヒカク シケン
Search this article
Abstract
A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects betwen the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration.
Journal
-
- Hinyokika Kiyo
-
Hinyokika Kiyo 57 (1), 7-13, 2011-01
泌尿器科紀要刊行会
- Tweet
Details 詳細情報について
-
- CRID
- 1050001202301477248
-
- NII Article ID
- 120002770966
-
- NII Book ID
- AN00208315
-
- ISSN
- 00181994
-
- HANDLE
- 2433/135441
- 10069/27364
-
- NDL BIB ID
- 10955151
-
- Text Lang
- ja
-
- Article Type
- departmental bulletin paper
-
- Data Source
-
- IRDB
- NDL
- CiNii Articles